Advanced search
Publication Cover
Current Medical Research and Opinion Volume 23, 2007 - Issue 4
Submit an article Journal homepage
182
Views
27
CrossRef citations to date
0
Altmetric
Brief Report

An economic assessment of analogue basal–bolus insulin versus human basal–bolus insulin in subjects with type 1 diabetes in the UK

Andrew J. Palmer IMS Health AG, Allschwil/Basel, Switzerland, Allschwil/Basel, SwitzerlandCorrespondence[email protected]
,
William J. Valentine IMS Health AG, Allschwil/Basel, Switzerland, Allschwil/Basel, Switzerland
,
Joshua A. Ray IMS Health AG, Allschwil/Basel, Switzerland, Allschwil/Basel, Switzerland
,
Volker Foos IMS Health AG, Allschwil/Basel, Switzerland, Allschwil/Basel, Switzerland
,
Francesco Lurati IMS Health AG, Allschwil/Basel, Switzerland, Allschwil/Basel, Switzerland
,
Inger Smith Novo Nordisk Limited, Crawley, UK
,
Morten Lammert Novo Nordisk A/S, Bagsværd, Denmark
&
Stéphane Roze IMS Health AG, Allschwil/Basel, Switzerland, Allschwil/Basel, Switzerland
 show all
Pages 895-901 | Accepted 22 Feb 2007, Published online: 16 Mar 2007

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Marc Evans, Phil McEwan & Volker Foos. (2015) Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice—a case-based evaluation. Journal of Medical Economics 18:2, pages 96-105.
Read now
Dong-Churl Suh & Mark Aagren. (2011) Cost–effectiveness of insulin detemir: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 11:6, pages 641-655.
Read now
Jean-Pierre Le Floch. (2010) Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics. Diabetes, Metabolic Syndrome and Obesity 3, pages 197-213.
Read now

Articles from other publishers (24)

Hailey Saunders, Ba’ Pham, Desmond Loong, Sujata Mishra, Huda M. Ashoor, Jesmin Antony, Nazia Darvesh, Silkan K. Bains, Margaret Jamieson, Donna Plett, Srushhti Trivedi, Catherine H. Yu, Sharon E. Straus, Andrea C. Tricco & Wanrudee Isaranuwatchai. (2022) The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review. Value in Health 25:7, pages 1235-1252.
Crossref
Alice M. Ellyson & Anirban Basu. (2021) Do pharmaceutical prices rise anticipating branded competition?. Health Economics 30:5, pages 1070-1081.
Crossref
Marc Evans, Roopa Mehta, Jens Gundgaard & Barrie Chubb. (2018) Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting. Diabetes Therapy 9:5, pages 1919-1930.
Crossref
Dalia Dawoud, Elisabetta Fenu, Bernard Higgins, David Wonderling & Stephanie A. Amiel. (2017) Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis. Value in Health 20:10, pages 1279-1287.
Crossref
Asrul Akmal Shafie, Chin Hui Ng, Yui Ping Tan & Nathorn Chaiyakunapruk. (2016) Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. PharmacoEconomics 35:2, pages 141-162.
Crossref
Fernanda O Laranjeira, Everton Nunes da Silva & Maurício G Pereira. (2016) Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil. PLOS ONE 11:12, pages e0167039.
Crossref
Phil McEwan, Hayley Bennett, Jonathan Fellows, Jennifer Priaulx & Klas Bergenheim. (2016) The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus. PLOS ONE 11:9, pages e0162441.
Crossref
Cristóbal Morales, Daniel de Luis, Antonio Ramírez de Arellano, Maria Giovanna Ferrario & Luis Lizán. (2015) Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain. Diabetes Therapy 6:4, pages 593-610.
Crossref
Marc Evans & Phil McEwan. (2015) Clinical and cost–effectiveness of insulin degludec: from clinical trials to clinical practice. Journal of Comparative Effectiveness Research 4:3, pages 279-286.
Crossref
George Grunberger. (2014) Insulin Analogs—Are They Worth It? Yes!. Diabetes Care 37:6, pages 1767-1770.
Crossref
Michèle Sennhauser & Peter Zweifel. (2014) Ist ein neues Arzneimittel sein Geld wert? Wessen Geld? – Bewertung eines neuen Diabetes-Präparats mit Hilfe eines Discrete-Choice-Experiments. PharmacoEconomics German Research Articles 11:2, pages 45-63.
Crossref
W. J. Valentine, J. Jendle, M. Saraheimo, B. Thorsteinsson, R. F. Pollock & M. Lammert. (2012) Evaluating the cost‐effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabetic Medicine 29:3, pages 303-312.
Crossref
Li Yang, Torsten Christensen, Fengyu Sun & Jinghua Chang. (2012) Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study. Value in Health 15:1, pages S56-S59.
Crossref
William J. Valentine, Mark Aagren, Mattias Haglund, Åsa Ericsson & Manuela H. Gschwend. (2010) Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scandinavian Journal of Public Health 39:1, pages 79-87.
Crossref
Matthias von Herrath. (2010) Combination therapies for Type 1 diabetes: why not now?. Immunotherapy 2:3, pages 289-291.
Crossref
Jason R. YoungCarrie Mcadam-Marx. (2010) Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog. Clinical Medicine Insights: Endocrinology and Diabetes 3, pages CMED.S5330.
Crossref
Cosimo Giannini, Angelika Mohn & Francesco Chiarelli. (2009) Technology and the issue of cost/benefit in diabetes. Diabetes/Metabolism Research and Reviews 25:S1, pages S34-S44.
Crossref
Julia M. Bottomley & Frank D. Raymond. (2009) Pharmaco-economic issues for diabetes therapy. Insulin 4:1, pages 32-60.
Crossref
. (2008) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 15:4, pages 383-400.
Crossref
Luigi F Meneghini. (2008) Insulin detemir: a long-acting insulin analog for the treatment of Type 1 and 2 diabetes. Therapy 5:4, pages 513-529.
Crossref
Steven Leichter. (2008) Is the use of insulin analogues cost-effective?. Advances in Therapy 25:4, pages 285-299.
Crossref
Julia M. Bottomley & Frank D. Raymond. (2007) Pharmaco-economic issues for diabetes therapy. Best Practice & Research Clinical Endocrinology & Metabolism 21:4, pages 657-685.
Crossref
Linda B. Haas. (2007) Optimizing Insulin Use in Type 2 Diabetes: Role of Basal and Prandial Insulin in Long-Term Care Facilities. Journal of the American Medical Directors Association 8:8, pages 502-510.
Crossref
Javier Morales. (2007) Defining the Role of Insulin Detemir in Basal Insulin Therapy. Drugs 67:17, pages 2557-2584.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.